LY4405094 in healthy volunteers and people with Alzheimer's disease
Tests the safety of LY4405094 in healthy adults and adults with Alzheimer's.
Plain-language title generated from the registry record
Registry title: A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
Key facts
- Where
- Bunkyō City and Ōbu, JapanSee the 2 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT07787182, who can take part
Where in Japan
- The University of Tokyo HospitalBunkyō City, JapanNot yet recruiting
- National Center for Geriatrics and GerontologyŌbu, JapanNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07787182EU 2026-527295-81-00
- Record updated
- 22 October 2026
- Original description
The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream. For healthy participants, the study also looks at how much LY4405094 gets into the fluid around the brain and lasts up to 13 weeks and will include a 4-day stay in the Clinical Research Unit (CRU). For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 25 weeks and will include a 3-day stay in the CRU.Read full original descriptionShow less
A Placebo-Controlled, Single- and Multiple-Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream. For healthy participants, the study also looks at how much LY4405094 gets into the fluid around the brain and lasts up to 13 weeks and will include a 4-day stay in the Clinical Research Unit (CRU). For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 25 weeks and will include a 3-day stay in the CRU.
Inclusion: Participants must meet eligibility criteria in the ATMP screening protocol before entry into the treatment study.
Exclusion: Have known allergies to LY4405094, related compounds (including remternetug), or any components of the formulation, including LY4405094; Have known allergic reactions to adhesive or hydrogels or a family history of adhesive skin allergies.